Yang Xi, Yi Cheng, Luo Na, Gong Changyang
Department of Medical Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Curr Drug Metab. 2014;15(6):632-49. doi: 10.2174/1389200215666140926154443.
Cancer is still considered to be one of the most severe diseases so far. Multidrug resistance (MDR) is a major obstacle against curative cancer chemotherapy. The over-expression of drug efflux pumps in cellular membrane plays a critical role in preventing cancer cells from conventional chemotherapy. Nanotechnology is emerging as a class of therapeutics for MDR. This review mainly focuses on some pivotal strategies to combat MDR, including the enhanced permeability and retention (EPR) effect, stealth nanoparticles to prolong circulation time, endosomal escape, active drug delivery, stimuli sensitive drug release, and targeted co-delivery of different compounds. While convinced challenges need combatting, large numbers of preclinical studies strongly suggest that nanomedicine formations have potential application for improving the treatment of MDR.
癌症至今仍被认为是最严重的疾病之一。多药耐药性(MDR)是根治性癌症化疗的主要障碍。细胞膜上药物外排泵的过度表达在阻止癌细胞接受传统化疗方面起着关键作用。纳米技术正在成为一类治疗多药耐药性的疗法。本综述主要关注一些对抗多药耐药性的关键策略,包括增强渗透滞留(EPR)效应、延长循环时间的隐形纳米颗粒、内体逃逸、主动药物递送、刺激敏感药物释放以及不同化合物的靶向共递送。尽管存在需要应对的明显挑战,但大量临床前研究有力地表明,纳米药物制剂在改善多药耐药性治疗方面具有潜在应用价值。